Actinogen Medical

Company Announcements:
(reported by the Company)
No items found
Elevator Pitch:

Actinogen Medical is an Australian clinical stage biotechnology company. The company is focused on the treatment of Alzheimer's Disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious conditions of Alzheimer’s and dementia.

Category: Health & biotech
Operational Status: Active
ASX Listing Code (if applicable): ACW
Year of Commencement:

2/1 Walker Avenue, West Perth WA 6005

State: Western Australia
Overseas Operations: No
Key Personnel:
Awards won:
Current Period Rank:

WA Annual Rank 2016: 84


    January, 2018

    Appointed George Morstyn as non-executive director

    August, 2017

    Enrolled its first UK patient into XanADu, its international Phase II efficacy and safety trial of Xanamem therapy in patients with mild Alzheimer’s disease

    March, 2017

    Appointed Geoff Brooke as chairperson

    February, 2017

    Received UK approval to conduct its Phase II clinical trial of Xanamem

    January, 2017

    US FDA has approved Actinogen Medical's investigational new drug application to initiate XanADu


Company News:

NOTE: Company News, Milestones and Funding are as collected by Techboard as part of our Monthly Startup Ranking

Amount Seeking:
Type of capital raise:
Pre-money valuation:
ESIC Status:
ESIC Upload:
Future Intentions:
Investment Video:
Investment Pitchdeck:
Investment URL:
Investment Phone:
Investment Email:

Leave a Reply